DOCSLIB.ORG

Osteopenia in X-Linked Hyper-Igm Syndrome Reveals a Regulatory Role for CD40 Ligand in Osteoclastogenesis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Osteopenia in X-Linked Hyper-Igm Syndrome Reveals a Regulatory Role for CD40 Ligand in Osteoclastogenesis Osteopenia in X-linked hyper-IgM syndrome reveals a regulatory role for CD40 ligand in osteoclastogenesis Eduardo Lopez-Granados*†, Stephane T. Temmerman*, Lynne Wu*, James C. Reynolds‡, Dean Follmann§, Shuying Liu*, David L. Nelson¶, Frank Rauchʈ, and Ashish Jain*,** *Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892; ‡Nuclear Medicine Department, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892; §Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892; ¶Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; and ʈGenetics Unit, Shriners Hospital, McGill University, Montreal, QC, Canada H3G 1A6 Edited by Richard A. Flavell, Yale University School of Medicine, New Haven, CT, and approved November 28, 2006 (received for review July 11, 2006) We report that osteopenia is a prominent and previously unap- soluble factors may have a synergistic effect on the expression of preciated clinical feature of patients with X-linked hyper-IgM target genes that mediate osteoclast activation. syndrome, an inherited immune deficiency disorder caused by CD40 ligand (CD40L or CD154) is expressed on the surface mutations in the gene encoding CD40 ligand (CD40L). We therefore of activated CD4ϩ T cells. The gene encoding CD40L lies on the conducted studies to determine the relationship between CD40L X chromosome, and alterations in CD40L cause X-linked hyper- and osteoclastogenesis. Recognizing that activated T cells express IgM syndrome (XHIM), which is a rare immune deficiency surface receptor activator of NF-␬B ligand (RANKL) and can induce disorder that is inherited as an X-linked inherited trait and is osteoclast differentiation of myeloid cells expressing RANK, we usually only found in males (13–15). As a consequence of ϩ assessed the capacity of wild-type T cells and CD40L؊/؊ T cells to deficiency in CD40L, patient CD4 T cells are unable to induce osteoclastogenesis in vitro. Relative to wild-type T cells, stimulate CD40-expressing B cells to switch Ig production from activated CD40L؊/؊ T cells from both humans and mice promoted IgM to IgG, or IgA. Thus, XHIM patients have skewed IgM robust osteoclast differentiation of myeloid cells. Whereas acti- antibody responses and a markedly diminished or absent IgG .(vated CD40L؊/؊ T cells had normal expression of RANKL, they were response to protein antigens (16 deficient in IFN-␥ production. In subsequent studies, we cultured CD40L stimulation of antigen-presenting cells (APCs) in- activated CD40L؊/؊ T cells in the presence of IFN-␥, and we found duces up-regulation of CD80/86 and IL-12 secretion. IL-12 that the osteoclastic capacity of CD40L؊/؊ T cells could be greatly secretion by APCs leads to the differentiation of naı¨ve T cells ␥ diminished. These results show that CD40L can influence RANKL into TH1 effector cells capable of producing IFN- . The impor- signaling through T cell priming, and thus they demonstrate a tance of this interaction has been shown in both humans and regulatory role for CD40L in bone mineralization that is absent in mice with CD40L deficiency, where the population of antigen- patients with X-linked hyper-IgM syndrome. primed memory T cells is markedly diminished, and activated T cells fail to secrete IFN-␥ or induce IL-12 secretion in APCs (17, osteoclast ͉ IFN-␥ ͉ receptor activator of NF-␬B ligand (RANKL) ͉ 18). Clinically, such impairments in T cell immunity predispose bone homeostasis ͉ T cells XHIM patients to opportunistic infections with Pneumocystis carinii and Cryptosporidium (19–21). In addition, reports of hepatobiliary cancer, carcinoid tumor, and other neoplasms in one is subject to continuous remodeling by the coupled patients with XHIM suggest defective immune surveillance (22). Bactivity of two different cells types: osteoblasts that synthe- The immune defects in patients with XHIM have consequences size new bone matrix and osteoclasts that lead to its resorption early in life. In the only large retrospective study of 56 patients, (1). The discovery of receptor activator of nuclear factor the Kaplan–Meier survival rate was 20% by the age of 25 years ␬ (NF)- B ligand (RANKL; also known as TRANCE), a member despite i.v. Ig therapy and antibiotic prophylaxis (19). of the TNF superfamily of cytokines, has led to a deeper We noted that clinic patients with XHIM had spontaneous rib understanding of osteoclastogenesis, the process of osteoclast fractures without antecedent trauma. This clinical observation differentiation and activation. RANKL is synthesized by bone prompted us to investigate whether CD40L deficiency may marrow stromal cells, osteoblasts, and activated T cells (2–5). Its contribute to an imbalance in bone mineral homeostasis. In this interaction with RANK on the surface of myeloid precursor cells induces their differentiation into osteoclasts. In addition, stim- ulation of mature osteoclasts by RANKL leads to their activation Author contributions: E.L.-G., D.L.N., and A.J. designed research; E.L.-G., S.T.T., L.W., J.C.R., and bone resorption in vivo (4–7). The majority of skeletal D.F., S.L., D.L.N., F.R., and A.J. performed research; and E.L.-G. and A.J. wrote the paper. diseases associated with low BMD are related to excessive The authors declare no conflict of interest. osteoclast activity (8). This article is a PNAS direct submission. The RANK signaling pathway has several levels of regulation. Freely available online through the PNAS open access option. Osteoprotegerin (OPG) is an osteoclastogenesis-inhibitory fac- Abbreviations: APC, antigen-presenting cell; BMD, bone mineral density; BMM, bone tor that is secreted by osteoblasts and functions as a soluble marrow monocyte/macrophage precursor; CD40L, CD40 ligand; DXA, dual-energy x-ray absorptiometry; M-CSF, macrophage colony-stimulating factor; NTX, N-terminal telopep- decoy receptor for RANKL (9). RANK stimulation leads to the tide of type I collagen; OPG, osteoprotegerin; PBMC, peripheral blood mononuclear cell; recruitment of the tumor necrosis factor receptor-associated RANKL, receptor activator of NF-␬B ligand; TRAF6, tumor necrosis factor receptor-associ- factor 6 (TRAF6), which then regulates the downstream acti- ated factor 6; TRAP, tartrate-resistant acid phosphatase; XHIM, X-linked hyper-IgM syndrome. vation of the I␬B kinase complex and the c-Jun N-terminal ␥ †Present address: Nuffield Department of Clinical Medicine, University of Oxford, kinase signaling pathways. IFN- signaling leads to the proteo- Oxford OX3 9DU, United Kingdom. somal degradation of TRAF6, and it can therefore have an **To whom correspondence should be addressed at: Room 5W-3950, Clinical Research inhibitory effect on RANK intracellular signaling and osteoclast Center, National Institutes of Health, Bethesda, MD 20892. E-mail: [email protected]. ␣ ␤ activity (10). In contrast, IL-1, TNF- , and TGF- can enhance This article contains supporting information online at www.pnas.org/cgi/content/full/ osteoclastogenesis in vitro (11, 12). IL-1 and TNF-␣ are members 0605715104/DC1. of the TNF family of proteins, and increased signaling by these © 2007 by The National Academy of Sciences of the USA 5056–5061 ͉ PNAS ͉ March 20, 2007 ͉ vol. 104 ͉ no. 12 www.pnas.org͞cgi͞doi͞10.1073͞pnas.0605715104 Downloaded by guest on September 24, 2021 work we show that, compared with age- and sex-matched normal controls, XHIM patients have significantly lower bone mineral density (BMD) and have elevated levels of N-terminal telopep- tides of type I collagen (NTX), a urinary marker indicative of osteoclast activity (23–25). We further demonstrate that acti- vated CD4ϩ CD40LϪ/Ϫ T cells from either humans or mice have normal expression of RANKL and promote marked osteoclas- togenesis of myeloid cells because of their defect in T cell priming and IFN-␥ production. Taken together, these findings suggest an important regulatory role for CD40L in osteoclasto- genesis, which is impaired in patients with XHIM. Results Patient Characteristics. Fourteen patients from 13 unrelated fam- ilies (ages 6–33 years) were enrolled into the study. The diagnosis of XHIM was established in each patient by medical and family history, Ig profile, and the presence of the CD40L mutation and/or activated T cells that do not express CD40L. All patients presented in childhood with recurrent bacterial sinorespiratory infections and some experienced opportunistic infections. All patients after diagnosis received i.v. gamma globulin replace- ment therapy. During routine clinic visits, two of the patients were noted to have spontaneous rib fractures without a history of antecedent trauma. No significant abnormality was found in biochemical indices of calcium homeostasis. Specifically, serum calcium, serum phosphorus, 1,25-dihydroxyvitamin D3, 25- dihydroxyvitamin D3, and intact parathyroid hormone remained within the normal range. Bone Density, Histomorphometry, and NTX Measurements. BMD was analyzed by dual-energy x-ray absorptiometry (DXA) (26) at several skeletal locations in all 14 XHIM patients. The L1–L4 location in the posterior–anterior position was chosen for sta- Fig. 1. BMD and biochemical measurements of bone metabolism. (A) Re- tistical evaluation because pediatric reference values are avail- duced BMD in XHIM patients. The BMD (g/cm2) at the spinal L1–L4 position in able at this location and it allows the patients’ results to be the posterior–anterior projection for each patient was compared with an age- compared with age-matched male controls. Our group of XHIM and sex-matched control group. In each patient, the number of standard MEDICAL SCIENCES patients exhibited a Z score (number of SD away from the mean) deviations of the BMD value compared with the mean value for the control distribution that was markedly shifted to the negative values group (Z score; filled squares) is represented over the Gaussian distribution of compared with the distribution expected in a normal population the normal population. (B) Measurements of NTXs in 24-h urine samples of (Fig.
Load more

Recommended publications
  • RANKL As a Novel EMT Marker 858 Cell Research (2008) 18:858-870
    npg RANKL as a novel EMT marker 858 Cell Research (2008) 18:858-870. npg © 2008 IBCB, SIBS, CAS All rights reserved 1001-0602/08 $ 30.00 ORIGINAL ARTICLE www.nature.com/cr Receptor activator of NF-κB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells Valerie A Odero-Marah1, Ruoxiang Wang1, Gina Chu1, Majd Zayzafoon2, Jianchun Xu1, Chunmeng Shi1, Fray F Marshall1, Haiyen E Zhau1, Leland WK Chung1 1Molecular Urology and Therapeutics Program, Department of Urology and Winship Cancer Institute, Emory University School of Medicine, 1365B Clifton Road, NE, Atlanta, GA 30322, USA; 2Department of Pathology, University of Alabamn, Birmingham, AL 35294, USA Epithelial-mesenchymal transition (EMT) in cancer describes the phenotypic and behavioral changes of cancer cells from indolent to virulent forms with increased migratory, invasive and metastatic potential. EMT can be induced by soluble proteins like transforming growth factor β1 (TGFβ1) and transcription factors including Snail and Slug. We uti- lized the ARCaPE/ARCaPM prostate cancer progression model and LNCaP clones stably overexpressing Snail to identify novel markers associated with EMT. Compared to ARCaPE cells, the highly tumorigenic mesenchymal ARCaPM and ARCaPM1 variant cells displayed a higher incidence of bone metastasis after intracardiac administration in SCID mice. ARCaPM and ARCaPM1 expressed mesenchymal stromal markers of vimentin and N-cadherin in addition to elevated levels of Receptor Activator of NF-κB Ligand (RANKL). We observed that both epidermal growth factor (EGF) plus TGFβ1 treatment and Snail overexpression induced EMT in ARCaPE and LNCaP cells, and EMT was associated with increased expression of RANKL protein.
    [Show full text]
  • RANK Interaction and Signaling − RANKL Structural and Functional
    Structural and Functional Insights of RANKL −RANK Interaction and Signaling Changzhen Liu, Thomas S. Walter, Peng Huang, Shiqian Zhang, Xuekai Zhu, Ying Wu, Lucy R. Wedderburn, Peifu This information is current as Tang, Raymond J. Owens, David I. Stuart, Jingshan Ren and of October 1, 2021. Bin Gao J Immunol published online 14 May 2010 http://www.jimmunol.org/content/early/2010/05/14/jimmun ol.0904033 Downloaded from Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: by guest on October 1, 2021 http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published May 14, 2010, doi:10.4049/jimmunol.0904033 The Journal of Immunology Structural and Functional Insights of RANKL–RANK Interaction and Signaling Changzhen Liu,*,†,1 Thomas S. Walter,‡,1 Peng Huang,x Shiqian Zhang,{ Xuekai Zhu,*,† Ying Wu,*,† Lucy R. Wedderburn,‖ Peifu Tang,x Raymond J. Owens,‡ David I. Stuart,‡ Jingshan Ren,‡ and Bin Gao*,†,‖ Bone remodeling involves bone resorption by osteoclasts and synthesis by osteoblasts and is tightly regulated by the receptor activator of the NF-kB ligand (RANKL)/receptor activator of the NF-kB (RANK)/osteoprotegerin molecular triad.
    [Show full text]
  • TRAIL and Cardiovascular Disease—A Risk Factor Or Risk Marker: a Systematic Review
    Journal of Clinical Medicine Review TRAIL and Cardiovascular Disease—A Risk Factor or Risk Marker: A Systematic Review Katarzyna Kakareko 1,* , Alicja Rydzewska-Rosołowska 1 , Edyta Zbroch 2 and Tomasz Hryszko 1 1 2nd Department of Nephrology and Hypertension with Dialysis Unit, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] (A.R.-R.); [email protected] (T.H.) 2 Department of Internal Medicine and Hypertension, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] * Correspondence: [email protected] Abstract: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a pro-apoptotic protein showing broad biological functions. Data from animal studies indicate that TRAIL may possibly contribute to the pathophysiology of cardiomyopathy, atherosclerosis, ischemic stroke and abdomi- nal aortic aneurysm. It has been also suggested that TRAIL might be useful in cardiovascular risk stratification. This systematic review aimed to evaluate whether TRAIL is a risk factor or risk marker in cardiovascular diseases (CVDs) focusing on major adverse cardiovascular events. Two databases (PubMed and Cochrane Library) were searched until December 2020 without a year limit in accor- dance to the PRISMA guidelines. A total of 63 eligible original studies were identified and included in our systematic review. Studies suggest an important role of TRAIL in disorders such as heart failure, myocardial infarction, atrial fibrillation, ischemic stroke, peripheral artery disease, and pul- monary and gestational hypertension. Most evidence associates reduced TRAIL levels and increased TRAIL-R2 concentration with all-cause mortality in patients with CVDs. It is, however, unclear Citation: Kakareko, K.; whether low TRAIL levels should be considered as a risk factor rather than a risk marker of CVDs.
    [Show full text]
  • Increased Expression of CD154 and FAS in SLE Patients’ Lymphocytes Maria Elena Manea, Ruediger B
    Increased expression of CD154 and FAS in SLE patients’ lymphocytes Maria Elena Manea, Ruediger B. Mueller, Doru Dejica, Ahmed Sheriff, Georg Schett, Martin Herrmann, Peter Kern To cite this version: Maria Elena Manea, Ruediger B. Mueller, Doru Dejica, Ahmed Sheriff, Georg Schett, et al.. Increased expression of CD154 and FAS in SLE patients’ lymphocytes. Rheumatology International, Springer Verlag, 2009, 30 (2), pp.181-185. 10.1007/s00296-009-0933-4. hal-00568285 HAL Id: hal-00568285 https://hal.archives-ouvertes.fr/hal-00568285 Submitted on 23 Feb 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Increased expression of CD154 and FAS in SLE patients’ lymphocytes Maria Elena Manea1‡, MD, Ruediger B. Mueller2,3‡, MD, Doru Dejica1, PhD, Ahmed Sheriff2, PhD, Georg Schett2, MD, Martin Herrmann2, PhD, Peter Kern4, MD 1 Department of Immunopathology. “Iuliu Hatieganu" University of Medicine and Pharmacy, Str Croitorilor no 19-21, 3400 Cluj-Napoca, Romania. 2 Department for Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nürnberg, Germany 3 Departement of Rheumatologie, Kantonsspital St. Gallen, Switzerland 4 Franz von Prümmer Klinik, Bahnhofstraße 16, 97769 Bad Brückenau, Germany ‡ both authors equally contributed to the work Address correspondence and reprint requests to: Ruediger B.
    [Show full text]
  • The Roadmap of RANKL/RANK Pathway in Cancer
    cells Review The Roadmap of RANKL/RANK Pathway in Cancer Sandra Casimiro 1,* , Guilherme Vilhais 2, Inês Gomes 1 and Luis Costa 1,3,* 1 Luis Costa Laboratory, Instituto de Medicina Molecular—João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, 1649-028 Lisboa, Portugal; [email protected] 2 Faculdade de Medicina da Universidade de Lisboa, 1649-028 Lisboa, Portugal; [email protected] 3 Oncology Division, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, 1649-028 Lisboa, Portugal * Correspondence: [email protected] (S.C.); [email protected] (L.C.) Abstract: The receptor activator of the nuclear factor-κB ligand (RANKL)/RANK signaling pathway was identified in the late 1990s and is the key mediator of bone remodeling. Targeting RANKL with the antibody denosumab is part of the standard of care for bone loss diseases, including bone metastases (BM). Over the last decade, evidence has implicated RANKL/RANK pathway in hormone and HER2-driven breast carcinogenesis and in the acquisition of molecular and phenotypic traits associated with breast cancer (BCa) aggressiveness and poor prognosis. This marked a new era in the research of the therapeutic use of RANKL inhibition in BCa. RANKL/RANK pathway is also an important immune mediator, with anti-RANKL therapy recently linked to improved response to immunotherapy in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). This review summarizes and discusses the pre-clinical and clinical evidence of the relevance of the RANKL/RANK pathway in cancer biology and therapeutics, focusing on bone metastatic disease, BCa onset and progression, and immune modulation.
    [Show full text]
  • Cell-Expressed CD154 in Germinal Centers Expression, Regulation
    Expression, Regulation, and Function of B Cell-Expressed CD154 in Germinal Centers Amrie C. Grammer, Richard D. McFarland, Jonathan Heaney, Bonnie F. Darnell and Peter E. Lipsky This information is current as of September 25, 2021. J Immunol 1999; 163:4150-4159; ; http://www.jimmunol.org/content/163/8/4150 Downloaded from References This article cites 74 articles, 33 of which you can access for free at: http://www.jimmunol.org/content/163/8/4150.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 25, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1999 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Expression, Regulation, and Function of B Cell-Expressed CD154 in Germinal Centers1 Amrie C. Grammer,* Richard D. McFarland,† Jonathan Heaney,* Bonnie F. Darnell,† and Peter E. Lipsky2* Activated B cells and T cells express CD154/CD40 ligand in vitro. The in vivo expression and function of B cell CD154 remain unclear and therefore were examined.
    [Show full text]
  • B Cell Checkpoints in Autoimmune Rheumatic Diseases
    REVIEWS B cell checkpoints in autoimmune rheumatic diseases Samuel J. S. Rubin1,2,3, Michelle S. Bloom1,2,3 and William H. Robinson1,2,3* Abstract | B cells have important functions in the pathogenesis of autoimmune diseases, including autoimmune rheumatic diseases. In addition to producing autoantibodies, B cells contribute to autoimmunity by serving as professional antigen- presenting cells (APCs), producing cytokines, and through additional mechanisms. B cell activation and effector functions are regulated by immune checkpoints, including both activating and inhibitory checkpoint receptors that contribute to the regulation of B cell tolerance, activation, antigen presentation, T cell help, class switching, antibody production and cytokine production. The various activating checkpoint receptors include B cell activating receptors that engage with cognate receptors on T cells or other cells, as well as Toll-like receptors that can provide dual stimulation to B cells via co- engagement with the B cell receptor. Furthermore, various inhibitory checkpoint receptors, including B cell inhibitory receptors, have important functions in regulating B cell development, activation and effector functions. Therapeutically targeting B cell checkpoints represents a promising strategy for the treatment of a variety of autoimmune rheumatic diseases. Antibody- dependent B cells are multifunctional lymphocytes that contribute that serve as precursors to and thereby give rise to acti- cell- mediated cytotoxicity to the pathogenesis of autoimmune diseases
    [Show full text]
  • The Role of the Immune Checkpoint Modulator OX40 and Its Ligand in NK Cell Immunosurveillance and Acute Myeloid Leukemia
    1 The role of the immune checkpoint modulator OX40 and its ligand in NK cell 2 immunosurveillance and acute myeloid leukemia 3 Running title: OX40-OX40L in NK cell immunosurveillance 4 Keywords: OX40, AML, NK cells, immunotherapy, checkpoint 5 Tina Nuebling*1, Carla Emilia Schumacher*1,2, Martin Hofmann3, Ilona Hagelstein1, Benjamin Joachim 6 Schmiedel1, Stefanie Maurer1, Birgit, Federmann4, Kathrin Rothfelder1, Malte Roerden2, Daniela Dörfel1,2, 7 Pascal Schneider5, Gundram Jung3, Helmut Rainer Salih1,2 8 1 9 Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK) and German 10 Cancer Research Center (DKFZ), Heidelberg, Germany 2 11 Department of Hematology and Oncology, Eberhard Karls University, Tuebingen, Germany 3 12 Department of Immunology, Eberhard Karls University, Tuebingen, Germany 13 4 Department of Pathology, Eberhard Karls University, Tuebingen, Germany 14 5 Department of Biochemistry, Epalinges, Switzerland 15 16 *these authors contributed equally to this work 17 18 Corresponding Author: 19 Helmut R. Salih, M.D. 20 Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK) and German 21 Cancer Research Center (DKFZ) 22 Department of Hematology and Oncology, Eberhard Karls University 23 Otfried-Mueller Str. 10, 72076 Tuebingen, Germany 24 Phone: +49-7071-2983275; Fax: +49-7071-293671; Email: [email protected] 25 26 Funding: Supported by grants from the Deutsche Forschungsgemeinschaft (NU341/1-1, SA1360/7-3, 27 SFB685, project A07), Deutsche Krebshilfe (projects 111828 and 111134). PS is supported by grants from 28 the Swiss National Science Foundation. 29 Conflict-of-interest disclosure: The authors declare no potential conflicts of interest. 30 31 32 Text word count: 4347; Abstract word count: 238 33 5 figures, 2 tables, 4 supplementary figures 34 References: 50 1 35 Abstract 36 The TNF receptor family member OX40 promotes activation and proliferation of T cells, which 37 fuels present attempts to modulate this immune checkpoint to reinforce anti-tumor immunity.
    [Show full text]
  • (Blys) on Diabetes-Related Periodontitis
    ORIGINAL RESEARCH Immunology Preliminary findings on the possible role of B-lymphocyte stimulator (BLyS) on diabetes-related periodontitis Marx Haddley Ferreira Abstract: The possible role of B-cell growth and differentiation- DRUMOND(a) related cytokines on the pathogenesis of diabetes-related periodontitis Luciano Eduardo PUHL(a) has not been addressed so far. The aim of this study was to evaluate Poliana Mendes DUARTE(b) the effects of diabetes mellitus (DM) on the gene expression of Tamires Szeremeske de proliferation-inducing ligand (APRIL) and B-lymphocyte stimulator MIRANDA(c) (BLyS), two major cytokines associated to survival, differentiation Juliana Trindade and maturation of B cells in biopsies from gingival tissue with CLEMENTE-NAPIMOGA(a) periodontitis. Gingival biopsies were obtained from subjects with Daiane Cristina PERUZZO(a) periodontitis (n = 17), with periodontitis and DM (n = 19) as well as Elizabeth Ferreira MARTINEZ(a) from periodontally and systemically healthy controls (n = 10). Gene Marcelo Henrique NAPIMOGA(a) expressions for APRIL, BLyS, RANKL, OPG, TRAP and DC-STAMP were evaluated using qPCR. The expressions APRIL, BLyS, RANKL, (a) Faculdade São Leopoldo Mandic, Instituto OPG, TRAP and DC-STAMP were all higher in both periodontitis de Pesquisas São Leopoldo Mandic, groups when compared to the control group (p < 0.05). Furthermore, Campinas, SP, Brazil. the expressions of BLyS, TRAP and RANKL were significantly higher (b) University of Florida, College of Dentistry, in the subjects with periodontitis and DM when compared to those Department of Periodontology, Gainesville, FL, USA. with periodontitis alone (p < 0.05). The mRNA levels of BLyS correlated positively with RANKL in the subjects with periodontitis and DM (c) Guarulhos University, Dental Research Division, Department of Periodontology, São (p < 0.05).
    [Show full text]
  • Multimeric Forms of 4-1BBL As Stimulators of T Cells for Adoptive Immunotherapy
    Kornbluth et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P246 http://www.immunotherapyofcancer.org/content/2/S3/P246 POSTERPRESENTATION Open Access Multimeric forms of 4-1BBL as stimulators of T cells for adoptive immunotherapy Richard S Kornbluth1*, Victoria Snarsky1, Geoffrey W Stone2 From Society for Immunotherapy of Cancer 29th Annual Meeting National Harbor, MD, USA. 6-9 November 2014 Members of the TNF SuperFamily of ligands (TNFSFs) Authors’ details 1Multimeric Biotherapeutics, Inc., La Jolla, CA, USA. 2University of Miami, have significant potential as immuno-oncology therapeu- Miller School of Medicine, Miami, FL, USA. tic agents. The TNFSFs are trimeric membrane proteins that can be cleaved into soluble single trimers. While Published: 6 November 2014 the soluble single trimers can be easily prepared and studied, they have little or no activity in vivo. This defi- ciency is caused by the need to cluster their cognate doi:10.1186/2051-1426-2-S3-P246 Cite this article as: Kornbluth et al.: Multimeric forms of 4-1BBL as receptors in the plane of the membrane in order to stimulators of T cells for adoptive immunotherapy. Journal for induce a supramolecular signaling complex on the cyto- ImmunoTherapy of Cancer 2014 2(Suppl 3):P246. plasmic side of the plasma membrane. For the TNFSF ligands, this requires that they be used as many-trimer multimers that mimic the natural expression of many trimers on the surface of stimulating cells. To meet this need, we prepared fusion proteins comprised of the extracellular domains of TNFSF ligands joined to a nat- ural protein that provides a multimerization scaffold.
    [Show full text]
  • Belongs to the TNF Family a New Class of Reverse Signaling
    A New Class of Reverse Signaling Costimulators Belongs to the TNF Family Mingyi Sun and Pamela J. Fink This information is current as J Immunol 2007; 179:4307-4312; ; of September 27, 2021. doi: 10.4049/jimmunol.179.7.4307 http://www.jimmunol.org/content/179/7/4307 References This article cites 85 articles, 38 of which you can access for free at: Downloaded from http://www.jimmunol.org/content/179/7/4307.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision http://www.jimmunol.org/ • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: by guest on September 27, 2021 http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. THE JOURNAL OF IMMUNOLOGY BRIEF REVIEWS A New Class of Reverse Signaling Costimulators Belongs to the TNF Family Mingyi Sun and Pamela J. Fink1 Recent evidence shows that many molecules of the TNF still remains unclear (7). The N-terminal cytoplasmic domains family serve as counter-receptors, inducing costimulation of most TNF family members are conserved across species but through reverse signals in addition to delivering signals not between family members, suggesting that the intracellular through their respective TNF receptors.
    [Show full text]
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.
    [Show full text]